2021/05/15 更新

写真a

ツカモト ヨシヒロ
塚本 佳広
TSUKAMOTO Yoshihiro
所属
医歯学総合病院 脳神経外科 助教
職名
助教
外部リンク

学位

  • 博士(医学) ( 2016年3月   新潟大学 )

  • 学位(医学) ( 2007年3月   新潟大学 )

研究分野

  • ライフサイエンス / 脳神経外科学

経歴

  • 新潟大学   医歯学総合病院 脳神経外科   助教

    2019年6月 - 現在

  • 新潟大学   医歯学総合病院 脳神経外科   特任助教

    2019年4月 - 2019年5月

  • 新潟大学   医歯学総合病院 脳神経外科   特任助教

    2016年4月 - 2017年3月

所属学協会

 

論文

  • MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas 査読 国際誌

    Hideaki Abe, Manabu Natsumeda, Masayasu Okada, Jun Watanabe, Yoshihiro Tsukamoto, Yu Kanemaru, Junichi Yoshimura, Makoto Oishi, Rintaro Hashizume, Akiyoshi Kakita, Yukihiko Fujii

    Frontiers in Oncology9   1568 - 1568   2020年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    © Copyright © 2020 Abe, Natsumeda, Okada, Watanabe, Tsukamoto, Kanemaru, Yoshimura, Oishi, Hashizume, Kakita and Fujii. Diffuse midline gliomas (DMGs) show resistance to many chemotherapeutic agents including temozolomide (TMZ). Histone gene mutations in DMGs trigger epigenetic changes including DNA hypomethylation, one of which is a frequent lack of O6-methyl-guanine-DNA methyltransferase (MGMT) promoter methylation, resulting in increased MGMT expression. We established the NGT16 cell line with HIST1H3B K27M and ACVR1 G328E gene mutations from a DMG patient and used this cell line and other DMG cell lines with H3F3A gene mutation (SF7761, SF8628, JHH-DIPG1) to analyze MGMT promoter methylation, MGMT protein expression, and response to TMZ. Three out of 4 DMG cell lines (NGT16, SF8628, and JHH-DIPG1) had unmethylated MGMT promoter, increased MGMT expression, and showed resistance to TMZ treatment. SF7761 cells with H3F3A gene mutation showed MGMT promoter methylation, lacked MGMT expression, and sensitivity to TMZ treatment. NGT16 line showed response to ALK2 inhibitor K02288 treatment in vitro. We confirmed in vitro that MGMT expression contributes to TMZ resistance in DMG cell lines. There is an urgent need to develop new strategies to treat TMZ-resistant DMGs.

    DOI: 10.3389/fonc.2019.01568

    Scopus

    PubMed

    researchmap

  • Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy. 査読

    Kanemaru Y, Natsumeda M, Okada M, Saito R, Kobayashi D, Eda T, Watanabe J, Saito S, Tsukamoto Y, Oishi M, Saito H, Nagahashi M, Sasaki T, Hashizume R, Aoyama H, Wakai T, Kakita A, Fujii Y

    Acta neuropathologica communications7 ( 1 ) 119   2019年7月

  • Podoplanin Expression and IDH-Wildtype Status Predict Venous Thromboembolism in Patients with High-Grade Gliomas in the Early Postoperative Period. 査読

    Watanabe J, Natsumeda M, Okada M, Kanemaru Y, Tsukamoto Y, Oishi M, Kakita A, Fujii Y

    World neurosurgery   2019年5月

  • High detection rate of MYD88 mutations in cerebrospinal fluid from patients with central nervous system lymphomas. 査読

    Watanabe J, Matsumeda M, Olada M, Kobayashi D, Kanemaru Y, Tsukamoto Y, Oishi M, Kakita A, Fujii Y

    JCO Precis Oncol,   e1 - e10   2019年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1200/PO.18.00308.

    researchmap

  • [Posterior Quadrantectomy for Infant with Refractory Epilepsy:A Case Report]. 査読

    Saito T, Oishi M, Fukuda M, Tsukamoto Y, Ohashi T, Watanabe J, Nemoto T, Kawaguchi T, Fujii Y

    No shinkei geka. Neurological surgery47 ( 3 ) 349 - 356   2019年3月

  • EGFRvIII Is Expressed in Cellular Areas of Tumor in a Subset of Glioblastoma. 査読

    Nozawa T, Okada M, Natsumeda M, Eda T, Abe H, Tsukamoto Y, Okamoto K, Oishi M, Takahashi H, Fujii Y, Kakita A

    Neurologia medico-chirurgica59 ( 3 ) 89 - 97   2019年3月

  • MGMT Expression Contributes to Temozolomide Resistance in H3K27M-Mutant Diffuse Midline Gliomas and MGMT Silencing to Temozolomide Sensitivity in IDH-Mutant Gliomas. 査読

    Abe H, Natsumeda M, Kanemaru Y, Watanabe J, Tsukamoto Y, Okada M, Yoshimura J, Oishi M, Fujii Y

    Neurologia medico-chirurgica58 ( 7 ) 290 - 295   2018年7月

  • Reliable diagnosis of IDH-mutant glioblastoma by 2-hydroxyglutarate detection: a study by 3-T magnetic resonance spectroscopy. 査読 国際誌

    Manabu Natsumeda, Kunio Motohashi, Hironaka Igarashi, Takanori Nozawa, Hideaki Abe, Yoshihiro Tsukamoto, Ryosuke Ogura, Masayasu Okada, Tsutomu Kobayashi, Hiroshi Aoki, Hitoshi Takahashi, Akiyoshi Kakita, Kouichirou Okamoto, Tsutomu Nakada, Yukihiko Fujii

    Neurosurgical review41 ( 2 ) 641 - 647   2018年4月

     詳細を見る

    記述言語:英語  

    We have previously reported that reliable detection of 2-hydroxyglutarate (2HG) in isocitrate dehydrogenase (IDH)-mutant WHO grade 2 and 3 gliomas is possible utilizing 3.0-T single-voxel magnetic resonance spectroscopy (SVMRS). We set out to determine whether the same method could be applied to detect 2HG in IDH-mutant glioblastoma. Forty-four patients harboring glioblastoma underwent pre-operative MRS evaluation to detect 2HG and other metabolites. Presence of IDH-mutations was determined by IDH1 R132H immunohistochemical analysis and DNA sequencing of surgically obtained tissues. Six out of 44 (13.6%) glioblastomas were IDH-mutant. IDH-mutant glioblastoma exhibited significantly higher accumulation of 2HG (median 3.191 vs. 0.000 mM, p < 0.0001, Mann-Whitney test). A cutoff of 2HG = 0.897 mM achieved high sensitivity (100.0%) and specificity (92.59%) in determining IDH-mutation in glioblastoma. Glioblastoma with high 2HG accumulation did not have significantly longer overall survival than glioblastoma with low 2HG accumulation (p = 0.107, log-rank test). Non-invasive and reliable detection of 2HG in IDH-mutant glioblastoma was possible by 3.0-T SVMRS.

    DOI: 10.1007/s10143-017-0908-y

    PubMed

    researchmap

  • Long-term survivors of primary central nervous system lymphoma 査読

    Ryuya Yamanaka, Ken Morii, Masakazu Sano, Jumpei Homma, Naoki Yajima, Yoshihiro Tsukamoto, Ryouske Ogura, Manabu Natsumeda, Hiroshi Aoki, Katsuhiko Akiyama, Takafumi Saitoh, Hiroaki Hondoh, Atsushi Kawaguchi, Hitoshi Takahashi, Yukihiko Fujii

    JAPANESE JOURNAL OF CLINICAL ONCOLOGY47 ( 2 ) 101 - 107   2017年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:OXFORD UNIV PRESS  

    Objective: In this study, we provide long-term outcome data of patients with primary central nervous system lymphoma
    Methods: The long-term outcomes of PCNSL patients diagnosed between 1982 and 2006 were reviewed. Neurological late neurotoxicity symptoms, neuroradiological brain atrophy and leukoen-cephalopathy were evaluated. Surviving patients completed the Quality of Life Questionnaire-30 and Brain Cancer Module-20. The differences in overall survival were assessed using the Kaplan-Meier method and log-rank test. The differences between groups in terms of each investigated parameter were analyzed using the Wilcoxon signed-rank test
    Results: Among 112 PCNSL patients, there were 33 (29.4%) long-term (&gt; 5 years) survivors. The median survival of all long-term survivors was 105.7 months; of these, 8 (7.1%) were alive at the latest follow-up, with a mean survival time of 170.2 months (range, 121.8-286.4). Clinical assessment revealed severe neurotoxicity in 14 patients (42.4%), moderate neurotoxicity in 5 (15.1%), and normal status in 14 (42.4%). Correlations were seen between the neuroradiological imaging score changes and neurocognitive condition (P= 0.0001), neurocognitive condition and the whole brain irradiation dose (P= 0.0004), and atrophy and the whole brain irradiation dose (P= 0.0035).
    Conclusions: A more severe clinical condition was found to be associated with increasing age and whole brain irradiation dose in long-term survivors with PCNSL.

    DOI: 10.1093/jjco/hyw171

    Web of Science

    PubMed

    researchmap

  • Late relapse of primary central nervous system lymphoma 査読

    Ryuya Yamanaka, Ken Morii, Yoshikatsu Shinbo, Masakazu Sano, Jumpei Homma, Naoto Tsuchiya, Naoki Yajima, Yoshihiro Tsukamoto, Ryouske Ogura, Manabu Natsumeda, Hiroshi Aoki, Katsuhiko Akiyama, Takafumi Saitoh, Tetsuro Tamura, Hiroaki Hondoh, Atsushi Kawaguchi, Hitoshi Takahashi, Yukihiko Fujii

    LEUKEMIA & LYMPHOMA58 ( 2 ) 475 - 477   2017年2月

     詳細を見る

    記述言語:英語   出版者・発行元:TAYLOR & FRANCIS LTD  

    DOI: 10.1080/10428194.2016.1201570

    Web of Science

    PubMed

    researchmap

  • Chemical Screening Identifies EUrd as a Novel Inhibitor Against Temozolomide-Resistant Glioblastoma-Initiating Cells 査読

    Yoshihiro Tsukamoto, Naoki Ohtsu, Smile Echizenya, Satoko Otsuguro, Ryosuke Ogura, Manabu Natsumeda, Mizuho Isogawa, Hiroshi Aoki, Satoshi Ichikawa, Masahiro Sakaitani, Akira Matsuda, Katsumi Maenaka, Yukihiko Fujii, Toru Kondo

    STEM CELLS34 ( 8 ) 2016 - 2025   2016年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WILEY  

    Glioblastoma (GBM), one of the most malignant human cancers, frequently recurs despite multi-modal treatment with surgery and chemo/radiotherapies. GBM-initiating cells (GICs) are the likely cell-of-origin in recurrences, as they proliferate indefinitely, form tumors in vivo, and are resistant to chemo/radiotherapies. It is therefore crucial to find chemicals that specifically kill GICs. We established temozolomide (the standard medicine for GBM)-resistant GICs (GICRs) and used the cells for chemical screening. Here, we identified 1-(3-C-ethynyl-beta-D-ribopentofuranosyl) uracil (EUrd) as a selective drug for targeting GICRs. EUrd induced the death in GICRs more effectively than their parental GICs, while it was less toxic to normal neural stem cells. We demonstrate that the cytotoxic effect of EUrd on GICRs partly depended on the increased expression of uridine-cytidine kinase-like 1 (UCKL1) and the decreased one of 5'-nucleotidase cytosolic III (NT5C3), which regulate uridine-monophosphate synthesis positively and negatively respectively. Together, these findings suggest that EUrd can be used as a new therapeutic drug for GBM with the expression of surrogate markers UCKL1 and NT5C3.

    DOI: 10.1002/stem.2380

    Web of Science

    PubMed

    researchmap

  • Primary central nervous system lymphomas and related diseases: Pathological characteristics and discussion of the differential diagnosis 査読

    Yasuo Sugita, Hiroko Muta, Koichi Ohshima, Motohiro Morioka, Yoshihiro Tsukamoto, Hitoshi Takahashi, Akiyoshi Kakita

    NEUROPATHOLOGY36 ( 4 ) 313 - 324   2016年8月

     詳細を見る

    記述言語:英語   出版者・発行元:WILEY-BLACKWELL  

    Although primary diffuse large B-cell lymphomas of the CNS are designated as primary CNS lymphomas according to the WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue in 2008, a variety of other lymphomas (Burkitt lymphomas, EBV-positive diffuse large B-cell lymphoma of the elderly) and related diseases (lymphomatoid granulomatosis) that are also found in the CNS have been spotlighted in recent years. The histopathology of primary CNS Burkitt lymphomasmimics that of primary diffuse large B-cell lymphomas of the CNS after steroid administration. Therefore, for correct diagnosis of the involved lymphoma, comprehensive fluorescent in situ hybridization analysis for c-MYC and BCL2 is recommended in all primary CNS lymphoma cases with aggressive clinical course, multifocal involvement of the CNS, and a high proliferation index. The pathological characteristics of primary CNS EBV-positive diffuse large B-cell lymphoma of the elderly have similarities with those of the latency phenotype III, EBV lymphoproliferative disorders that arise in the setting of immunodeficiency. These age-related lymphomas usually occur in elderly immunocompetent patients, and the incidence of this disease was estimated to range from 4.0% to 13.6% of all primary CNS lymphomas. Shorter overall survival has been reported for patients with this disease. Lymphomatoid granulomatosis (LYG) is a systemic, EBV-driven, angiocentric and angiodestructive lymphoproliferative disorder. Primary LYG that shows distinct clinicopathological features compared with systemic LYG was recently reported. Finally, this review focuses on the relationship between primary CNS lymphomas and demyelinating diseases, and the concomitant use of intraoperative cytology and frozen sections that are helpful in rapid intraoperative diagnosis.

    DOI: 10.1111/neup.12276

    Web of Science

    PubMed

    researchmap

  • Immunohistochemical profiles of IDH1, MGMT and P53: Practical significance for prognostication of patients with diffuse gliomas 査読

    Ryosuke Ogura, Yoshihiro Tsukamoto, Manabu Natsumeda, Mizuho Isogawa, Hiroshi Aoki, Tsutomu Kobayashi, Seiichi Yoshida, Kouichiro Okamoto, Hitoshi Takahashi, Yukihiko Fujii, Akiyoshi Kakita

    NEUROPATHOLOGY35 ( 4 ) 324 - 335   2015年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:WILEY-BLACKWELL  

    Genetic and epigenetic status, including mutations of isocitrate dehydrogenase (IDH) and TP53 and methylation of O-6-methylguanine-DNA methyltransferase (MGMT), are associated with the development of various types of glioma and are useful for prognostication. Here, using routinely available histology sections from 312 patients with diffuse gliomas, we performed immunohistochemistry using antibodies specific for IDH1 mutation, MGMT methylation status, and aberrant p53 expression to evaluate the possible prognostic significance of these features. With regard to overall survival (OS), univariate analysis indicated that an IDH1-positive profile in patients with glioblastoma (GBM), anaplastic astrocytoma (AA), anaplastic oligoastrocytoma and oligodendroglioma, or a MGMT-negative profile in patients with GBM and AA were significantly associated with a favorable outcome. Multivariate analysis revealed that both profiles were independent factors influencing prognosis. The OS of patients with IDH1-positive/MGMT-negative profiles was significantly longer than that of patients with negative/negative and negative/positive profiles. A p53 profile was not an independent prognostic factor. However, for GBM/AA patients with IDH1-negative/MGMT-negative profiles, p53 overexpression was significantly associated with an unfavorable outcome. Thus, the immunohistochemical profiles of IDH1 and MGMT are of considerable significance in gliomas, and a combination of IDH1, MGMT and p53 profiles may be useful for prognostication of GBM/AA.

    DOI: 10.1111/neup.12196

    Web of Science

    PubMed

    researchmap

  • Successful removal of a huge hypervascular tentorial cavernous angioma after preoperative endovascular embolization 査読

    Junichi Yoshimura, Yoshihiro Tsukamoto, Masakazu Sano, Hitoshi Hasegawa, Kazuhiko Nishino, Akihiko Saito, Masafumi Fukuda, Kouichirou Okamoto, Yukihiko Fujii

    JOURNAL OF NEUROSURGERY-PEDIATRICS14 ( 1 ) 43 - 47   2014年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:AMER ASSOC NEUROLOGICAL SURGEONS  

    The authors report a rare case of a huge hypervascular tentorial cavernous angioma treated with preoperative endovascular embolization, followed by successful gross-total removal. A 15-year-old girl presented with scintillation, diplopia, and papilledema. Computed tomography and MRI studies revealed a huge irregularly shaped tumor located in the right occipital and suboccipital regions. The tumor, which had both intra- and extradural components, showed marked enhancement and invasion of the overlying occipital bone. Angiography revealed marked tumor stain, with blood supply mainly from a large branch of the left posterior meningeal artery. Therefore, this lesion was diagnosed as a tentorium-based extraaxial tumor. For differential diagnosis, meningioma, hemangiopericytoma, and malignant skull tumor were considered. Tumor feeders were endovascularly embolized with particles of polyvinyl alcohol. On the following day, the tumor was safely gross totally removed with minimum blood loss. Histopathological examination confirmed the diagnosis of cavernous angioma. To date, there have been no reports of tentorium-based cavernous angiomas endovascularly embolized preoperatively. A tentorial cavernous angioma is most likely to show massive intraoperative bleeding. Therefore, preoperative embolization appears to be quite useful for safe maximum resection. Hence, the authors assert that the differential diagnosis of tentorium-based tumors should include tentorial cavernous angioma, for which preoperative endovascular embolization should be considered.

    DOI: 10.3171/2014.4.PEDS13628

    Web of Science

    PubMed

    researchmap

  • Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy 査読

    Manabu Natsumeda, Hironaka Igarashi, Toshiharu Nomura, Ryosuke Ogura, Yoshihiro Tsukamoto, Tsutomu Kobayashi, Hiroshi Aoki, Kouichirou Okamoto, Akiyoshi Kakita, Hitoshi Takahashi, Tsutomu Nakada, Yukihiko Fujii

    ACTA NEUROPATHOLOGICA COMMUNICATIONS2   158   2014年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:BIOMED CENTRAL LTD  

    Introduction: Previous magnetic resonance spectroscopy (MRS) and mass spectroscopy studies have shown accumulation of 2-hydroxyglutarate (2HG) in mutant isocitrate dehydrogenase (IDH) gliomas. IDH mutation is known to be a powerful positive prognostic marker in malignant gliomas. Hence, 2HG accumulation in gliomas was assumed to be a positive prognostic factor in gliomas, but this has not yet been proven. Here, we analyzed 52 patients harboring World Health Organization (WHO) grade II and III gliomas utilizing 3.0-tesla MRS.
    Results: Mutant IDH gliomas showed significantly higher accumulation of 2HG (median 5.077 vs. 0.000, p = 0.0002, Mann-Whitney test). 2HG was detectable in all mutant IDH gliomas, whereas in 10 out of 27 (37.0%) wild-type IDH gliomas, 2HG was below the detectable range (2HG = 0) (p = 0.0003, chi-squared test). Screening for IDH mutation by 2HG analysis was highly sensitive (cutoff 2HG = 1.489 mM, sensitivity 100.0%, specificity 72.2%). Gliomas with high 2HG accumulation had better overall survival than gliomas with low 2HG accumulation (p = 0.0401, Kaplan-Meier analysis).
    Discussion: 2HG accumulation detected by 3.0-tesla MRS not only correlates well with IDH status, but also positively correlates with survival in WHO grade II and III gliomas.

    DOI: 10.1186/s40478-014-0158-y

    Web of Science

    PubMed

    researchmap

  • Advantages of dose-dense methotrexate protocol for primary central nervous system lymphoma: Comparison of two different protocols at a single institution 査読

    Hiroshi Aoki, Ryosuke Ogura, Yoshihiro Tsukamoto, Masayasu Okada, Manabu Nat Sumeda, Mizuho Isogawa, Seiichi Yoshida, Yukihiko Fujii

    Neurologia Medico-Chirurgica53 ( 11 ) 797 - 804   2013年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The efficacy and toxicity of high-dose methotrexate (HD-MTX)-based chemotherapy were retrospectively reviewed in patients with primary central nervous system lymphoma (PCNSL). All immunocompetent patients with histologically or radiographically diagnosed PCNSL treated between 2006 and 2012 at Niigata University Hospital were enrolled. Thirty-eight patients with a diagnosis of PCNSL were treated with one of two regimens during different time periods. During the first period, from 2006 to 2009, three 3-week cycles of MPV (MTX + procarbazine + vincristine) were administered (MPV3 group). In the second period, from 2010 to 2012, five 2-week cycles of MTX were administered (MTX5 group). High-dose cytarabine was used in both groups following HD-MTX-based chemotherapy. Whole-brain radiotherapy was used for patients who did not attain a complete response (CR) based on magnetic resonance images. In the MPV3 group, 20 out of 23 patients (87%) completed the planned treatment. The CR rate after chemotherapy was 30%, and 57% after radiation therapy. Thirteen out of 15 patients (87%) in the MTX5 group completed the planned treatment. The CR rates after chemotherapy and radiation therapy were 53% and 93%, respectively. Renal dysfunction was assessed by measuring creatinine clearance rates, which were very similar in both groups. In terms of hematologic toxicity and other adverse reactions, there was no significant difference between the two groups. In conclusion, dose-dense MTX chemotherapy improved outcome with acceptable toxicity compared with the treatment schedule for three cycles of MPV treatment.

    DOI: 10.2176/nmc.oa2013-0195

    Scopus

    PubMed

    researchmap

  • Transarterial embolisation for refractory bilateral chronic subdural hematomas in a case with dentatorubral-pallidoluysian atrophy 査読

    Yoshihiro Tsukamoto, Makoto Oishi, Junnsuke Shinbo, Yukihiko Fujii

    ACTA NEUROCHIRURGICA153 ( 5 ) 1145 - 1147   2011年5月

     詳細を見る

    記述言語:英語   出版者・発行元:SPRINGER WIEN  

    DOI: 10.1007/s00701-010-0891-3

    Web of Science

    PubMed

    researchmap

▶ 全件表示

MISC

  • 診断 悪性神経膠腫における術後静脈血栓塞栓症危険因子の検討 ポドプラニンとIDH変異の関係

    棗田 学, 渡邉 潤, 岡田 正康, 金丸 優, 塚本 佳広, 大石 誠, 柿田 明美, 藤井 幸彦

    Brain Tumor Pathology36 ( Suppl. ) 070 - 070   2019年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本脳腫瘍病理学会  

    researchmap

  • 小児脳腫瘍のトランスレーショナルリサーチと基礎研究 プレシジョン=メディシン念頭に入れた小児脳腫瘍のモデル確立の試み

    棗田 学, 金丸 優, 阿部 英明, 渡邉 潤, 塚本 佳広, 岡田 正康, 吉村 淳一, 大石 誠, 藤井 幸彦

    小児の脳神経44 ( 2 ) 143 - 143   2019年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本小児神経外科学会  

    researchmap

  • 7-tesla MR susceptibility-weighted imaging can dipict astrocytic and oligodendroglial pathology 査読

    Natsumeda Manabu, Matsuzawa Hitoshi, Tsukamoto Yoshihiro, Motohashi Kunio, Kanemaru Yu, Okamoto Kouichirou, Kakita Akiyoshi, Igarashi Hironaka, Nakata Tsutomu, Fujii Yukihiko

    BRAIN PATHOLOGY29   68 - 69   2019年2月

  • Gli3 INDUCES NEURONAL DIFFERENTIATION IN WNT- AND SHH-ACTIVATED MEDULLOBLASTOMA 査読

    Manabu Natsumeda, Hiroaki Miyahara, Junichi Yoshimura, Takanori Nozawa, Yoshihiro Tsukamoto, Takafumi Wataya, Charles Eberhart, Hitoshi Takahashi, Akiyoshi Kakita, Yukihiko Fujii

    NEURO-ONCOLOGY19   183 - 183   2017年11月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)   出版者・発行元:OXFORD UNIV PRESS INC  

    Web of Science

    researchmap

  • グリオーマにおけるhistone H3K9 methyltransferase阻害薬の有効性(その2)

    富澤 元, 服部 修太, 阿部 英明, 梨本 望, 野澤 孝徳, 塚本 佳広, 岡田 正康, 棗田 学, 藤井 幸彦

    Brain Tumor Pathology34 ( Suppl. ) 136 - 136   2017年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本脳腫瘍病理学会  

    researchmap

  • 分子病理と分子病態 Oncogenesis and Progression WNT群、SHH群におけるGli3高発現と神経細胞分化

    棗田 学, 吉村 淳一, 宮原 弘明, 野澤 孝徳, 塚本 佳広, 綿谷 崇史, Eberhart Charles, 高橋 均, 柿田 明美, 藤井 幸彦

    Brain Tumor Pathology34 ( Suppl. ) 073 - 073   2017年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本脳腫瘍病理学会  

    researchmap

  • H3F3A G34Rが認められたcerebral hemispheric glioblastomaの1例

    塚本 佳広, 野澤 孝徳, 伊藤 絢子, 阿部 英明, 小倉 良介, 五十川 瑞穂, 棗田 学, 青木 洋, 岡本 浩一郎, 高橋 均, 藤井 幸彦, 柿田 明美

    新潟医学会雑誌131 ( 5 ) 313 - 313   2017年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    researchmap

  • グリオーマにおけるhistone H3K9 methyltransferase阻害薬の有効性(その1)

    服部 修太, 富澤 元, 阿部 英明, 梨本 望, 野澤 孝徳, 塚本 佳広, 岡田 正康, 棗田 学, 藤井 幸彦

    Brain Tumor Pathology34 ( Suppl. ) 135 - 135   2017年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本脳腫瘍病理学会  

    researchmap

  • 脳実質びまん性に認められた小型リンパ球増殖性疾患の一手術例

    塚本 佳広, 野澤 孝徳, 渡邉 潤, 佐藤 朋江, 棗田 学, 大石 誠, 高橋 均, 杉田 保雄, 柿田 明美, 藤井 幸彦

    Brain Tumor Pathology34 ( Suppl. ) 138 - 138   2017年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本脳腫瘍病理学会  

    researchmap

  • 集学的治療を行ったH3.1 K27M mutationを有するDiffuse Intrinsic Pontine Gliomaの一例

    塚本 佳広, 吉村 淳一, 棗田 学, 大石 誠, 岡本 浩一郎, 藤井 幸彦

    小児の脳神経42 ( 2 ) 168 - 168   2017年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本小児神経外科学会  

    researchmap

  • PXA with anaplastic features with sarcomatous componentと組織診断した前頭葉腫瘍の1例

    小倉 良介, 伊藤 絢子, 塚本 佳広, 五十川 瑞穂, 齋藤 理恵, 青木 洋, 岡本 浩一郎, 藤井 幸彦, 高橋 均, 柿田 明美

    The Kitakanto Medical Journal66 ( 2 ) 172 - 173   2016年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:北関東医学会  

    researchmap

  • 3T-MRSを用いたグリオーマのIDH変異術前評価

    棗田 学, 五十嵐 博中, 野村 俊春, 小倉 良介, 塚本 佳広, 小林 勉, 青木 洋, 岡本 浩一郎, 中田 力, 藤井 幸彦

    CI研究37 ( 3-4 ) 105 - 110   2016年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本脳神経CI学会  

    2-ヒドロキシグルタル酸(2HG)は正常組織では殆ど検出されないが、IDH変異を有するグリオーマでは蓄積する。IDH変異を有するグリオーマ症例で、3T-single voxel Magnetic Resonance Spectroscopy(3T-SVMRS)を用いて、2HGを検出できることを報告した。その内容を、1)IDH変異と2HG、2)IDH変異を有するグリオーマの特異なbiology、3)3T-SVMRSの撮像条件、4)SVMRSによる2HGの検出、5)2HGの測定の臨床的意義、の5項目に分けて解説した。

    researchmap

  • 【シーン別画像診断のいま-社会的要求への対応と課題[Scene Vol.9] オートプシー・イメージング(Ai)第五弾-社会インフラとしてのAiの普及と適切な活用に向けて-】医学・教育・情報などの視点から考察するオートプシー・イメージング(Ai) 新潟大学脳研究所の取り組み 3T MRIを用いたAiと病理解剖

    塚本 佳広, 小倉 良介, 渡辺 将樹, 岡本 浩一郎, 五十嵐 博中, 柿田 明美

    INNERVISION31 ( 1 ) 45 - 47   2015年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)インナービジョン  

    新潟大学脳研究所は、脳神経外科と神経内科の臨床2科、神経病理部門、そして統合脳機能研究センターなどを有している。同センターの中田力名誉教授(当時・教授/センター長)の発案により実現した、3T MRIを用いた死後画像解析システムが稼働している。われわれのポリシーは、死亡時画像診断(以下、Ai)施行後直ちに病理解剖を行い、画像情報と組織所見を統合して病態理解につなげようとするものである。Aiを剖検の代替手段として行おうとするものではない。本稿では、神経疾患を対象として当研究所が取り組んでいる死後画像解析システムと病理解剖について紹介する。(著者抄録)

    researchmap

  • 悪性星細胞腫瘍におけるp53の発現意義

    小倉 良介, 塚本 佳広, 棗田 学, 五十川 瑞穂, 青木 洋, 小林 勉, 吉田 誠一, 高橋 均, 柿田 明美, 藤井 幸彦

    Brain Tumor Pathology32 ( Suppl. ) 105 - 105   2015年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本脳腫瘍病理学会  

    researchmap

  • グリオーマ幹細胞研究の取り組み

    塚本 佳広, 小倉 良介, 岡田 正康, 棗田 学, 五十川 瑞穂, 青木 洋, 吉田 誠一, 藤井 幸彦, 小林 勉

    新潟医学会雑誌128 ( 11 ) 610 - 610   2014年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟医学会  

    researchmap

  • 【マルチモダリティによるHead & Neck Imaging 2014 臨床編 最新技術が臨床にもたらす変革とベネフィット】MRIのストラテジー&アウトカム 臨床施設からの報告 脳腫瘍 神経膠腫の診断・鑑別診断、術前情報取得におけるMRIの有用性

    岡本 浩一郎, 野村 俊春, 倉部 聡, 塚本 佳広, 棗田 学, 小倉 良介, 五十川 瑞穂, 青木 洋, 金沢 勉, 淡路 正則, 稲川 正一, 五十嵐 博中, 藤井 幸彦

    INNERVISION29 ( 5 ) 21 - 24   2014年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)インナービジョン  

    脳腫瘍の画像診断は、(1)存在・局在診断(腫瘍性病変の検出と部位・進展範囲の把握)、(2)質的(腫瘍の組織型と悪性度)診断推定と鑑別診断、(3)術前情報取得、(4)術後評価、(5)治療効果判定のいずれにも大きく関与する。CTは、(1)(2)における腫瘍の石灰化の検出、(3)での頭蓋骨描出などにおいて有用であるが、MRI情報はすべての過程において重要である。本稿では、神経膠腫の(2)(3)における当施設でのMRI撮像について、症例を提示して示す。なお、3T MRI装置を用いたMRスペクトロスコピー(MRS)、arterial spin labeling(ASL)法による灌流MRI、拡散テンソル画像(DTI)、three dimensional anisotropy contrast(3D-AC)法による神経線維描出は、本学脳研究所統合脳機能研究センターの協力を得て行っている。(著者抄録)

    researchmap

  • マウス脳腫瘍モデルを用いた脳腫瘍幹細胞の分離培養法の確立

    五十川 瑞穂, 塚本 佳広, 小倉 良介, 岡田 正康, 棗田 学, 青木 洋, 吉田 誠一, 藤井 幸彦

    新潟県医師会報 ( 766 ) 10 - 12   2014年1月

     詳細を見る

    記述言語:日本語   出版者・発行元:新潟県医師会  

    researchmap

  • 硬膜への播種性再発と腫瘍内出血を繰り返した膠肉腫の一例

    青木 洋, 小倉 良介, 塚本 佳広, 棗田 学, 小林 勉, 岡本 浩一郎, 吉田 誠一, 柿田 明美, 高橋 均, 藤井 幸彦

    Brain Tumor Pathology30 ( Suppl. ) 157 - 157   2013年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本脳腫瘍病理学会  

    researchmap

▶ 全件表示